Adjunctive Ivermectin Mass Drug Administration for Malaria Control (MATAMAL)
Malaria,Falciparum, Neglected Tropical Diseases, Strongyloidiasis
About this trial
This is an interventional treatment trial for Malaria,Falciparum focused on measuring Vector Control, Mass Drug Administration, Integrated Disease Control, Malaria, Guinea Bissau, West Africa, Antimalarials, Ivermectin, Dihydroartemisinin, Piperaquine
Eligibility Criteria
Inclusion Criteria:
- Age over six months to receive dihydroartemisinin-piperaquine
- Height over 90cm or weight over 15kg to receive ivermectin or placebo
- Willingness to adhere to trial procedures
- Individual written, informed consent from the participant or parent/guardian in the case of participants below the age of 18 years (and assent in young people between the ages of 12 and 17 years of age)
Exclusion Criteria:
- Known severe chronic illness (AIDS, Tuberculosis, chronic malnutrition)
- Known hypersensitivity to either dihydroartemisinin-piperaquine or ivermectin
- Pregnancy (any trimester) and breastfeeding (for ivermectin (or placebo)) and pregnancy (first trimester only) (for dihydroartemisinin-piperaquine)
- Travel to a Loa loa endemic country (eg Central African Republic) (for ivermectin (or placebo))
- Concomitant drugs that influence cardiac function or affect the corrected QT interval (for dihydroartemisinin-piperaquine)
Sites / Locations
- Bijagos Archipelago (islands)Recruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Ivermectin Mass Drug Administration
Placebo Mass Drug Administration
Ivermectin and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.
Placebo and Dihydroartemisinin-piperaquine MDA will be given to all eligible participants in each cluster (island) in addition to the standard national malaria control programme interventions.